Combined Cardiac Damage Staging by Echocardiography and Cardiac Catheterization in Patients with Clinically Significant Aortic Stenosis.

aortic stenosis aortic valve replacement cardiac damage staging right heart catheterization transthoracic echocardiography

Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
16 Nov 2023
Historique:
received: 03 09 2023
revised: 08 11 2023
accepted: 09 11 2023
medline: 19 11 2023
pubmed: 19 11 2023
entrez: 18 11 2023
Statut: aheadofprint

Résumé

Cardiac damage (CD) staging enhances risk stratification in patients with clinically significant aortic stenosis (AS). We aimed to assess the prognostic value and reclassification rate of right heart catheterization (RHC) compared to echocardiography (TTE) in characterizing CD-staging at 3-year follow-up in patients with clinically significant AS; to identify patients that would benefit from RHC for prognostic stratification; to test the prognostic value of "combined" CD-staging. Observational cohort study of 432 AS patients undergoing TTE and RHC, divided into moderate/asymptomatic severe (m/asAS) and symptomatic severe AS (ssAS). Kaplan-Meier curves were used to compare survival. The accuracy in prognostic stratification was tested by AUC analysis and Delong's test. In both cohorts, TTE- and RHC-derived staging systems had prognostic value, although the agreement between them appeared moderate. A higher proportion of patients were assigned to Stage 2 by TTE, compared to RHC. Patients in TTE-derived Stage 2 had a high reclassification rate, with 40-50% presenting with right chambers involvement (stages 3-4) at RHC. "Discordant" cases were significantly older, with higher prevalence of atrial fibrillation, markedly elevated N-terminal pro-brain natriuretic peptide, higher left atrial volume indexed, E/e' and systolic pulmonary artery pressure versus "concordant" cases (p<0.05). The "combined" CD-staging, integrating TTE and RHC, was more accurate in predicting mortality than TTE-derived system (p<0.05). In patients with m/asAS and ssAS, the "combined" CD-staging, derived from TTE and RHC, was more accurate in predicting mortality than TTE. In a subset of AS patients, the integration of RHC may significantly improve prognostic stratification.

Sections du résumé

BACKGROUND BACKGROUND
Cardiac damage (CD) staging enhances risk stratification in patients with clinically significant aortic stenosis (AS). We aimed to assess the prognostic value and reclassification rate of right heart catheterization (RHC) compared to echocardiography (TTE) in characterizing CD-staging at 3-year follow-up in patients with clinically significant AS; to identify patients that would benefit from RHC for prognostic stratification; to test the prognostic value of "combined" CD-staging.
METHODS METHODS
Observational cohort study of 432 AS patients undergoing TTE and RHC, divided into moderate/asymptomatic severe (m/asAS) and symptomatic severe AS (ssAS). Kaplan-Meier curves were used to compare survival. The accuracy in prognostic stratification was tested by AUC analysis and Delong's test.
RESULTS RESULTS
In both cohorts, TTE- and RHC-derived staging systems had prognostic value, although the agreement between them appeared moderate. A higher proportion of patients were assigned to Stage 2 by TTE, compared to RHC. Patients in TTE-derived Stage 2 had a high reclassification rate, with 40-50% presenting with right chambers involvement (stages 3-4) at RHC. "Discordant" cases were significantly older, with higher prevalence of atrial fibrillation, markedly elevated N-terminal pro-brain natriuretic peptide, higher left atrial volume indexed, E/e' and systolic pulmonary artery pressure versus "concordant" cases (p<0.05). The "combined" CD-staging, integrating TTE and RHC, was more accurate in predicting mortality than TTE-derived system (p<0.05).
CONCLUSION CONCLUSIONS
In patients with m/asAS and ssAS, the "combined" CD-staging, derived from TTE and RHC, was more accurate in predicting mortality than TTE. In a subset of AS patients, the integration of RHC may significantly improve prognostic stratification.

Identifiants

pubmed: 37979721
pii: S0828-282X(23)01887-1
doi: 10.1016/j.cjca.2023.11.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Marta Belmonte (M)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Pasquale Paolisso (P)

Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Dario Tino Bertolone (DT)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Michele Mattia Viscusi (MM)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Emanuele Gallinoro (E)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; IRCCS Ospedale Galeazzi Sant'Ambrogio, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.

Elayne Kelen De Oliveira (EK)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Monika Shumkova (M)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Monika Beles (M)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Giuseppe Esposito (G)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Lucio Addeo (L)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Giulia Botti (G)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Interventional Cardiology Unit, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Ana Moya (A)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Attilio Leone (A)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.

Eric Wyffels (E)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Bernard De Bruyne (B)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium; Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.

Guy Van Camp (G)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Joseph Bartunek (J)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Emanuele Barbato (E)

Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy.

Martin Penicka (M)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.

Marc Vanderheyden (M)

Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium. Electronic address: marc.vanderheyden@olvz-aalst.be.

Classifications MeSH